Hodgkin lymphoma
Reed-Sternberg cells and the CD15/CD30 phenotype, PET/CT staging and GHSG risk groups, ABVD plus radiotherapy in early stage, BrECADD or nivolumab-AVD in advanced stage, bleomycin lung, salvage with transplant, and lifelong late-effect surveillance.
Tier 1Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- A B-cell lymphoma with scattered Reed-Sternberg cells in a large reactive infiltrate. About 10% of lymphomas.
- Bimodal age: young adults (20s and 30s) and over 60.
- Classic presentation: painless rubbery cervical or supraclavicular node, often with a mediastinal mass, B symptoms or itch.
Loading the rest of the note…
Finished reading?
Sources
- Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upEichenauer DA, André M, Borchmann P, Collins GP et al., European Hematology Association, HemaSphere 2026;10(6):e70422, 2026
- Optimal care pathway for people with Hodgkin and diffuse large B-cell lymphomas, 2nd editionAU/NZCancer Council Australia
- eviQ Haematology and BMT treatment protocols, Hodgkin lymphomaAU/NZCancer Institute NSW
- Schedule of Pharmaceutical Benefits, November 2026 (brentuximab vedotin)AU/NZAustralian Government Department of Health, Disability and Ageing, 1 November 2026
- Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage classical Hodgkin lymphoma (HD21)Borchmann P et al., Lancet 2024;404:341-52, 2024
- Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma (SWOG S1826)Herrera AF et al., N Engl J Med 2024;391:1379-89, 2024
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback